News Stories

Jacksonville, Florida - (August 25, 2022) - The American College of Cardiology (ACC) announced the release of the 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee. The new Expert Consensus Decision Pathway provides practical guidance for lowering LDL-C with nonstatin therapies.

Regeneron Pharmaceuticals, Inc. announced positive results from a Phase 3 trial evaluating Evkeeza® (evinacumab) in children aged 5 to 11 with homozygous familial hypercholesterolemia (HoFH). The trial met its primary endpoint, showing children who added investigational evinacumab to other lipid-lowering therapies reduced their low-density lipoprotein-cholesterol (LDL-C) by an average of 48% at week 24 of the study. Anne C.

Kowa Research Institute, Inc. has announced the decision to not continue its Phase 3 PROMINENT study. Read the press release. Kowa has indicated that full data will be shared at a future conference.